Patents by Inventor Amber C. Donahue

Amber C. Donahue has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • MLH1 METHYLATION ASSAY
    Publication number: 20240218430
    Abstract: The present technology relates to methods for excluding Lynch syndrome as a possible diagnosis in patients suffering from colorectal cancers or endometrial cancers. These methods are based on detecting the methylation status of the MLH1 promoter ‘C’ region in colorectal and endometrial cancer patients using an improved and highly sensitive methylation-specific multiplex ligation-dependent probe amplification (MS-MLPA) assay.
    Type: Application
    Filed: December 11, 2023
    Publication date: July 4, 2024
    Applicant: Quest Diagnostics Investments LLC
    Inventors: Amber C. Donahue, Feras Hantash
  • MLH1 methylation assay
    Patent number: 11840726
    Abstract: The present technology relates to methods for excluding Lynch syndrome as a possible diagnosis in patients suffering from colorectal cancers or endometrial cancers. These methods are based on detecting the methylation status of the MLH1 promoter ‘C’ region in colorectal and endometrial cancer patients using an improved and highly sensitive methylation-specific multiplex ligation-dependent probe amplification (MS-MLPA) assay.
    Type: Grant
    Filed: January 4, 2021
    Date of Patent: December 12, 2023
    Assignee: Quest Diagnostics Investments LLC
    Inventors: Amber C. Donahue, Feras Hantash
  • Methylated markers for colorectal cancer
    Patent number: 11486007
    Abstract: Disclosed herein is a combination of genomic sequences whose methylation patterns have utility for the improved detection and differentiation between colorectal neoplasms. Further disclosed herein are methods, nucleic acids and kits for detecting or differentiating between colorectal neoplasms.
    Type: Grant
    Filed: June 3, 2015
    Date of Patent: November 1, 2022
    Assignees: Quest Diagnostics Investments Incorporated, CLINICAL GENOMICS PTY LTD
    Inventors: Susanne Pedersen, Lawrence LaPointe, Rohan Baker, Amber C. Donahue, Yen-lin Peng, Frederic Waldman
  • MLH1 METHYLATION ASSAY
    Publication number: 20210130871
    Abstract: The present technology relates to methods for excluding Lynch syndrome as a possible diagnosis in patients suffering from colorectal cancers or endometrial cancers. These methods are based on detecting the methylation status of the MLH1 promoter ‘C’ region in colorectal and endometrial cancer patients using an improved and highly sensitive methylation-specific multiplex ligation-dependent probe amplification (MS-MLPA) assay.
    Type: Application
    Filed: January 4, 2021
    Publication date: May 6, 2021
    Applicant: Quest Diagnostics Investments LLC
    Inventors: Amber C. Donahue, Feras Hantash
  • MLH1 methylation assay
    Patent number: 10883138
    Abstract: The present technology relates to methods for excluding Lynch syndrome as a possible diagnosis in patients suffering from colorectal cancers or endometrial cancers. These methods are based on detecting the methylation status of the MLH1 promoter C region in colorectal and endometrial cancer patients using an improved and highly sensitive methylation-specific multiplex ligation-dependent probe amplification (MS-MLPA) assay.
    Type: Grant
    Filed: April 22, 2016
    Date of Patent: January 5, 2021
    Assignee: Quest Diagnostics Investments Incorporated
    Inventors: Amber C. Donahue, Feras Hantash
  • DISCRIMINATING BRAF MUTATIONS
    Publication number: 20200115760
    Abstract: Provided herein are methods for detecting and discriminating BRAF V600 mutations. Also provided herein are methods for diagnosis, prognosis, management, and treatment decisions of BRAF V600 mutation-related diseases or conditions.
    Type: Application
    Filed: September 20, 2019
    Publication date: April 16, 2020
    Applicant: Quest Diagnostics Investments LLC
    Inventors: Amber C. Donahue, Yen-lin Peng
  • Discriminating BRAF mutations
    Patent number: 10422008
    Abstract: Provided herein are methods for detecting and discriminating BRAF V600 mutations. Also provided herein are methods for diagnosis, prognosis, management, and treatment decisions of BRAF V600 mutation-related diseases or conditions.
    Type: Grant
    Filed: February 20, 2015
    Date of Patent: September 24, 2019
    Assignee: QUEST DIAGNOSTICS INVESTMENTS INCORPORATED
    Inventors: Amber C. Donahue, Yen-lin Peng
  • MLH1 METHYLATION ASSAY
    Publication number: 20180291426
    Abstract: The present technology relates to methods for excluding Lynch syndrome as a possible diagnosis in patients suffering from colorectal cancers or endometrial cancers. These methods are based on detecting the methylation status of the MLH1 promoter C region in colorectal and endometrial cancer patients using an improved and highly sensitive methylation-specific multiplex ligation-dependent probe amplification (MS-MLPA) assay.
    Type: Application
    Filed: April 22, 2016
    Publication date: October 11, 2018
    Applicant: Quest Diagnostics Investments Incorporated
    Inventors: Amber C. Donahue, Feras Hantash
  • METHYLATED MARKERS FOR COLORECTAL CANCER
    Publication number: 20170191135
    Abstract: Disclosed herein is a combination of genomic sequences whose methylation patterns have utility for the improved detection and differentiation between colorectal neoplasms. Further disclosed herein are methods, nucleic acids and kits for detecting or differentiating between colorectal neoplasms.
    Type: Application
    Filed: June 3, 2015
    Publication date: July 6, 2017
    Applicants: Quest Diagnostics Investments Incorporated, CLINICAL GENOMICS PTY LTD
    Inventors: Susanne Pedersen, Lawrence LaPointe, Rohan Baker, Amber C. Donahue, Yen-lin Peng, Frederic Waldman
  • DISCRIMINATING BRAF MUTATIONS
    Publication number: 20170175198
    Abstract: Provided herein are methods for detecting and discriminating BRAF V600 mutations. Also provided herein are methods for diagnosis, prognosis, management, and treatment decisions of BRAF V600 mutation-related diseases or conditions.
    Type: Application
    Filed: February 20, 2015
    Publication date: June 22, 2017
    Applicant: Quest Diagnostics Investments Incorporated
    Inventors: Amber C. Donahue, Yen-lin Peng